Research

Clinical Trials Funded by Drug and Device Companies

Registered clinical trials that drug and device companies funded in 2025, with the U.S. doctors named as investigators and the hospitals and sites where they run. Search by condition, drug, sponsor or trial number.

Condition, drug, sponsor or NCT number

Status Any statusRecruitingActive, not recruitingCompletedTerminated

Show

2,065 trials, most industry funding first

1. Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature

   Recruiting · Peripheral Vascular Diseases

   NCT04674969 · Boston Scientific Corporation · 47 U.S. investigators

   $734,500research payments

2. A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

   Recruiting · Phase 3 · Metastatic Gastric Adenocarcinoma

   NCT07043400 · Beone Medicines Ltd. · 13 U.S. investigators

   $734,498research payments

3. Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis

   Completed · Phase 3 · Psoriasis

   NCT04036435 · E.r. Squibb & Sons, L.l.c. · 58 U.S. investigators

   $734,367research payments

4. An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors

   Recruiting · Phase 1 · Advanced Solid Tumor

   NCT06589596 · Beone Medicines USA, Inc. · 6 U.S. investigators

   $734,261research payments

5. A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

   Terminated · Phase 3 · Migraine

   NCT04396574 · Eli Lilly and Company · 52 U.S. investigators

   $730,581research payments

6. A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

   Active, not recruiting · Phase 3 · Atopic Dermatitis

   NCT03568318 · AbbVie Inc. · 62 U.S. investigators

   $729,276research payments

7. A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

   Completed · Phase 4 · Rheumatoid Arthritis

   NCT03915964 · Eli Lilly and Company · 56 U.S. investigators

   $726,211research payments

8. A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults

   Completed · Phase 2 · Influenza

   NCT05606965 · ModernaTX, Inc. · 1 U.S. investigator

   $725,914research payments

9. Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)

   Enrolling by invitation · Phase 3 · Wheezing

   NCT06191315 · Sanofi US Services Inc. · 13 U.S. investigators

   $715,941research payments

10. Long-term Follow-up Study in Subjects Who Received Voretigene Neparvovec-rzyl (AAV2-hRPE65v2)

    Active, not recruiting · Inherited Retinal Dystrophy Due to RPE65 Mutations

    NCT03602820 · Spark Therapeutics, Inc. · 2 U.S. investigators

    $715,731research payments

11. Caris Biorepository Research Protocol

    Recruiting · Cancer

    NCT01499394 · Caris Mpi, Inc. · 28 U.S. investigators

    $715,325research payments

12. To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis

    Active, not recruiting · Phase 3 · End Stage Renal Disease (ESRD)

    NCT05908084 · Humacyte Global, Inc. · 28 U.S. investigators

    $712,156research payments

13. A Study to Assess the Bioavailability of Risankizumab Following Subcutaneous Administration With Prefilled Pen Relative to a Prefilled Syringe in Healthy Adult Participants

    Completed · Phase 1 · Healthy Volunteers

    NCT06946524 · AbbVie Inc. · 1 U.S. investigator

    $705,286research payments

14. A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.

    Active, not recruiting · Phase 3 · Chikungunya Virus

    NCT07003984 · Bavarian Nordic A/s · 9 U.S. investigators

    $704,398research payments

15. A Trial Investigating Lu AF28996 in Healthy Adult Participants

    Completed · Phase 1 · Healthy Participants

    NCT06277609 · H. Lundbeck A S · 3 U.S. investigators

    $704,090research payments

16. A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

    Recruiting · Phase 3 · Chronic Inflammatory Demyelinating Polyneuropathy

    NCT06290141 · Sanofi US Services Inc. · 20 U.S. investigators

    $703,523research payments

17. Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2)

    Completed · Phase 1 · Healthy Participants

    NCT07158411 · Deciphera Pharmaceuticals Inc. · 1 U.S. investigator

    $702,014research payments

18. Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor

    Active, not recruiting · Phase 1, Phase 2 · Advanced Malignant Neoplasm

    NCT03069469 · Deciphera Pharmaceuticals Inc. · 11 U.S. investigators

    $701,393research payments

19. Assessment of Combined CCM and ICD Device in HFrEF

    Active, not recruiting · Not applicable · Heart Failure

    NCT05855135 · Impulse Dynamics (USA) Inc. · 56 U.S. investigators

    $701,173research payments

20. A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)

    Active, not recruiting · Phase 1, Phase 2 · Chronic Kidney Disease (CKD)

    NCT05092347 · Regeneron Pharmaceuticals, Inc. · 9 U.S. investigators

    $698,447research payments

21. Pegtibatinase as a Treatment for Patients With Classical Homocystinuria (HCU) (Also Known as the COMPOSE Study)

    Recruiting · Phase 1, Phase 2 · Homocystinuria

    NCT03406611 · Travere Therapeutics, Inc. · 7 U.S. investigators

    $697,983research payments

22. A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

    Active, not recruiting · Phase 3 · Crohn's Disease

    NCT03105102 · AbbVie Inc. · 37 U.S. investigators

    $694,001research payments

23. Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib

    Recruiting · Phase 1 · Healthy

    NCT06997276 · Springworks Therapeutics, Inc. · 2 U.S. investigators

    $689,486research payments

24. Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

    Suspended · Phase 2 · Recurrent Grade 1 Follicular Lymphoma

    NCT06575686 · Ipsen Biopharmaceuticals, Inc · 1 U.S. investigator

    $689,381research payments

25. A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

    Completed · Phase 2 · Non-small Cell Lung Cancer

    NCT05635708 · Beigene, Ltd. · 5 U.S. investigators

    $685,268research payments

26. A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment

    Completed · Phase 3 · Metastatic Adenocarcinoma of the Pancreas

    NCT04083235 · Ipsen Bioscience Inc. · 46 U.S. investigators

    $683,114research payments

27. A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

    Active, not recruiting · Phase 2 · Ulcerative Colitis

    NCT06254950 · Takeda Pharmaceuticals U.S.A., Inc. · 13 U.S. investigators

    $681,961research payments

28. A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

    Active, not recruiting · Phase 3 · Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

    NCT03589326 · Takeda Pharmaceuticals U.S.A., Inc. · 12 U.S. investigators

    $679,384research payments

29. A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work

    Active, not recruiting · Phase 3 · Chronic Inflammatory Demyelinating Polyradiculoneuropathy

    NCT06290128 · Sanofi US Services Inc. · 19 U.S. investigators

    $678,914research payments

30. A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis

    Terminated · Phase 2 · Multiple Sclerosis

    NCT06220669 · Eli Lilly and Company · 10 U.S. investigators

    $677,864research payments

31. A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose

    Completed · Phase 1 · Hepatic Impairment

    NCT06908954 · Ipsen Bioscience Inc. · 3 U.S. investigators

    $675,241research payments

32. PET Study to Evaluate Brain Receptor Occupancy, Safety and Pharmacokinetics of ITI-1284 in Healthy Subjects

    Completed · Phase 1 · Healthy Volunteers

    NCT06299410 · Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) · 1 U.S. investigator

    $674,740research payments

33. Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

    Recruiting · Phase 1, Phase 2 · Non Small Cell Lung Carcinoma

    NCT06772623 · AbbVie Inc. · 16 U.S. investigators

    $674,222research payments

34. A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis

    Terminated · Phase 2 · Rheumatoid Arthritis

    NCT05516758 · Eli Lilly and Company · 41 U.S. investigators

    $673,438research payments

35. A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)

    Terminated · Phase 3 · Acute Myeloid Leukemia (AML)

    NCT04161885 · AbbVie Inc. · 32 U.S. investigators

    $669,846research payments

36. A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis

    Recruiting · Phase 2 · Rheumatoid Arthritis

    NCT06972446 · AbbVie Inc. · 28 U.S. investigators

    $668,972research payments

37. A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

    Active, not recruiting · Phase 3 · Chronic Rhinosinusitis With Nasal Polyps

    NCT06834360 · Sanofi US Services Inc. · 13 U.S. investigators

    $667,852research payments

38. Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

    Recruiting · Phase 2 · High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements

    NCT06649812 · AbbVie Inc. · 1 U.S. investigator

    $667,633research payments

39. A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment

    Completed · Phase 1 · Carcinoma, Non-Small-Cell Lung

    NCT05241834 · Eli Lilly and Company · 12 U.S. investigators

    $666,697research payments

40. Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

    Active, not recruiting · Phase 3 · Ulcerative Colitis

    NCT05782907 · AbbVie Inc. · 20 U.S. investigators

    $666,599research payments

41. Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis

    Recruiting · Phase 2 · Lewy Body Dementia Psychosis

    NCT07029581 · Acadia Pharmaceuticals Inc · 12 U.S. investigators

    $665,853research payments

42. Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa

    Active, not recruiting · Phase 3 · Glycogen Storage Disease Type II

    NCT04910776 · Genzyme Corporation · 5 U.S. investigators

    $665,445research payments

43. A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa

    Active, not recruiting · Phase 2 · Glycogen Storage Disease Type II-Pompe's Disease

    NCT03019406 · Genzyme Corporation · 3 U.S. investigators

    $664,175research payments

44. Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis

    Recruiting · Phase 2 · Psoriatic Arthritis

    NCT06865105 · AbbVie Inc. · 15 U.S. investigators

    $663,283research payments

45. A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

    Completed · Phase 3 · Duchenne Muscular Dystrophy

    NCT05096221 · Sarepta Therapeutics, Inc. · 21 U.S. investigators

    $662,570research payments

46. ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

    Recruiting · Phase 2 · Autosomal Dominant Polycystic Kidney Disease

    NCT06902558 · AbbVie Inc. · 28 U.S. investigators

    $658,703research payments

47. A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

    Recruiting · Phase 3 · Episodic Migraine

    NCT05711394 · AbbVie Inc. · 50 U.S. investigators

    $658,274research payments

48. A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and Adults With Hearing Loss Due to Otoferlin Mutations

    Recruiting · Phase 1, Phase 2 · Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)

    NCT05788536 · Regeneron Pharmaceuticals, Inc. · 5 U.S. investigators

    $657,795research payments

49. Project Mountain - Comparing SpO2 and SaO2 for Accuracy

    Recruiting · SpO2

    NCT06372106 · Philips North America LLC · 5 U.S. investigators

    $657,240research payments

50. HEAL-LAA Clinical Trial

    Completed · Not applicable · Atrial Fibrillation

    NCT05809596 · Boston Scientific Corporation · 43 U.S. investigators

    $656,759research payments

Sources: CMS Open Payments research payments, program year 2025 (trials with a ClinicalTrials.gov number), and ClinicalTrials.gov (U.S. National Library of Medicine). Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally.